This trial is studying how well olaparib works in treating patients with AML or MDS that has relapsed or is refractory. Olaparib may stop cancer cell growth by blocking enzymes needed for cell growth.
2 Primary · 4 Secondary · Reporting Duration: Up to 12 months
94 Total Participants · 1 Treatment Group
Primary Treatment: Olaparib · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: